These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 15912562

  • 21. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG, Kajdasz DK, Walker DJ, Raskin J, Tylee A.
    Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
    [Abstract] [Full Text] [Related]

  • 22. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
    Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M.
    Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
    [Abstract] [Full Text] [Related]

  • 23. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.
    Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, Walker DJ, Chappell AS.
    Semin Arthritis Rheum; 2010 Jun; 39(6):454-64. PubMed ID: 19152958
    [Abstract] [Full Text] [Related]

  • 24. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
    Dunner DL, Wilson M, Fava M, Kornstein S, Munoz R, O'Reardon J, Trivedi M, Wohlreich M.
    Depress Anxiety; 2008 Jun; 25(5):E1-8. PubMed ID: 17621644
    [Abstract] [Full Text] [Related]

  • 25. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials.
    Hall JA, Wang F, Oakes TM, Utterback BG, Crucitti A, Acharya N.
    Expert Opin Drug Saf; 2010 Jul; 9(4):525-37. PubMed ID: 20465525
    [Abstract] [Full Text] [Related]

  • 26. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS, Reines EH, Guiton C, Weiller E.
    Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
    [Abstract] [Full Text] [Related]

  • 27. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
    Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M.
    Depress Anxiety; 2006 Oct; 23(3):178-81. PubMed ID: 16528701
    [Abstract] [Full Text] [Related]

  • 28. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.
    J Psychiatr Res; 2007 Oct; 41(3-4):311-8. PubMed ID: 16934840
    [Abstract] [Full Text] [Related]

  • 29. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.
    Perahia DG, Quail D, Gandhi P, Walker DJ, Peveler RC.
    J Affect Disord; 2008 May; 108(1-2):33-41. PubMed ID: 17905442
    [Abstract] [Full Text] [Related]

  • 30. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
    Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, Bump RC, Duloxetine OAB Study Group.
    BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
    [Abstract] [Full Text] [Related]

  • 31. Time course of depression-symptom improvement during treatment with duloxetine.
    Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ.
    Depress Anxiety; 2005 Aug; 21(4):170-7. PubMed ID: 16035056
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 33. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
    Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD.
    J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
    [Abstract] [Full Text] [Related]

  • 34. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N, Schennach R, Riedel M, Möller HJ.
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [Abstract] [Full Text] [Related]

  • 35. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
    Baldwin DS, Loft H, Dragheim M.
    Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
    [Abstract] [Full Text] [Related]

  • 36. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
    Emslie GJ, Wells TG, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS.
    J Child Adolesc Psychopharmacol; 2015 May; 25(4):293-305. PubMed ID: 25978741
    [Abstract] [Full Text] [Related]

  • 37. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [Abstract] [Full Text] [Related]

  • 38. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
    Katona C, Hansen T, Olsen CK.
    Int Clin Psychopharmacol; 2012 Jul; 27(4):215-23. PubMed ID: 22572889
    [Abstract] [Full Text] [Related]

  • 39. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
    Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA.
    Int Clin Psychopharmacol; 2009 Nov; 24(6):296-305. PubMed ID: 19779354
    [Abstract] [Full Text] [Related]

  • 40. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.